Distinguished Clinical Professor University of Colorado School of Medicine, Colorado
Anecdotal reports of the efficacy of semaglutide and other Glucagon-Like Peptide-1 (GLP-1) receptor agonists as medical therapies for obesity have garnered widespread public attention, engendering ethical debates and leading to worldwide drug shortages. This focus session will provide a deep dive into GLP-1 receptor agonists to separate fact from fiction, including the exciting evidence for possible repurposing of GLP-1 receptor agonists to treat addictive disorders.
Learning Objectives:
Learners will be able to:
describe the preclinical evidence in favor of repurposing GLP-1 receptor agonists as possible addiction pharmacotherapies
recount the clinical trials studying the safety and efficacy of GLP-1 receptor agonists for addiction
consider methods for providing fair and just access to new, expensive medications like GLP-1 receptor agonists to all segments of society
